The U.S. Food and Drug Administration (FDA) recently sent letters to two companies selling unapproved products containing cannabidiol (CBD).
Selling the products violates the Federal Food, Drug and Cosmetic Act.
The law defines a drug as any nonfood product that is intended to affect the structure or function of the body or any product designed to treat a disease or otherwise have a therapeutic or medical use.
The FDA has only approved one prescription CBD product.
Letters were issued to Homero Corp DBA Natures CBD Oil Distribution for marketing and distributing CBD products as a treatment for opioid addiction and other serious diseases, and BIOTA Biosciences for marketing and distributing injectable CBD and curcumin products as an alternative to opioids and as a treatment for serious diseases.
Homero sells products under its own label and is a retailer for Green Roads CBD products.
BIOTA Biosciences markets private label CBD and wholesale CBD extracts.
“The opioid crisis continues to be a serious problem in the United States, and we will continue to crack down on companies that attempt to benefit from selling products with unfounded treatment claims,” Dr. Amy Abernethy, FDA principal deputy commissioner, said. “CBD has not been shown to treat opioid addiction.”